Onkológia 2/2022

How do we look at CDK4/6 inhibitors in palliative treatment today

Breast cancer is the most common cancer in women. It represents an incurable disease in the metastatic stage and treatment is aimed at prolonging survival and maintaining quality of life. About 70% of patients who have hormone receptor-positive cancer can use endocrine therapy. Its problem is the development of hormonal resistance, which shortens the period when it is effective. By understanding the mechanisms of resistance, it has been found that combination it with CDK4/6 inhibitors is one way to overcome it. This led to a change in the management of patients in the I. and II. lines of treatment. Combination therapy is highly effective, leads to improved survival parameters and at the same time it does not reduce patient’s quality of life due to its toxicity. Its strong position in global treatment guidelines is based on the results of registration studies, which confirmed prolongation of overall survival.

Keywords: breast cancer, CDK4/6 inhibitors, palliative treatment